The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function
Open accessAbstract
Polymorphic drug-metabolizing enzymes (DMEs) are responsible for the metabolism of the majority of psychotropic drugs. By explaining a large portion of variability in individual drug metabolism, pharmacogenetics offers a diagnostic tool in the burgeoning era of personalized medicine. This review updates existing evidence on the influence of pharmacogenetic variants on drug exposure and discusses the rationale for genetic testing in the clinical context. Dose adjustments based on pharmacogenetic knowledge are the first step to translate pharmacogenetics into clinical practice. However, also clinical factors, such as the consequences on toxicity and therapeutic failure, must be considered to provide clinical recommendations and assess the cost-effectiveness of pharmacogenetic treatment strategies. DME polymorphisms are relevant not only for clinical pharmacology and practice but also for research in psychiatry and neuroscience. Several DMEs, above all the cytochrome P (CYP) enzymes, are expressed in the brain, where they may contribute to the local biochemical homeostasis. Of particular interest is the possibility of DMEs playing a physiological role through their action on endogenous substrates, which may underlie the reported associations between genetic polymorphisms and cognitive function, personality and vulnerability to mental disorders. Neuroimaging studies have recently presented evidence of an effect of the CYP2D6 polymorphism on basic brain function. This review summarizes evidence on the effect of DME polymorphisms on brain function that adds to the well-known effects of DME polymorphisms on pharmacokinetics in explaining the range of phenotypes that are relevant to psychiatric practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
N-back working memory paradigm: a meta-analysis of normative functional neuroimaging studies.
Owen, A. M., McMillan, K. M., Laird, A. R., & Bullmore, E. (2005) · Human Brain Mapping · doi:10.1002/hbm.20131 · Cited by 3,560
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Modulating emotional responses: effects of a neocortical network on the limbic system
Hariri, A. R., Bookheimer, S. Y., & Mazziotta, J. C. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00009 · Cited by 1,277
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00898.x · Cited by 751
Badawi, A. F., Cavalieri, E. L., & Rogan, E. G. (2001) · Metabolism · doi:10.1053/meta.2001.25592 · Cited by 184
Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
Wang, J., Liu, Z., Wang, W., Chen, X., Shu, Y., He, N., & Zhou, H. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.116513 · Cited by 147
Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain
Kishimoto, W., Hiroi, T., Shiraishi, M., Osada, M., Imaoka, S., Kominami, S., Igarashi, T., & Funae, Y. (2004) · Endocrinology · doi:10.1210/en.2003-1109 · Cited by 90
Panagiotidis, G., Arthur, H. W., Lindh, J. D., Dahl, M.-L., & Sjöqvist, F. (2007) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31811f394d · Cited by 32
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Self-citationHicks, J., Sangkuhl, K., Swen, J., Ellingrod, V., Müller, D., Shimoda, K., Bishop, Jr., Kharasch, E., Skaar, T., Gaedigk, A., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.597 · Cited by 685
Self-citationBousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521
Esteves, F., Rueff, J., & Kranendonk, M. (2021) · Journal of Xenobiotics · doi:10.3390/jox11030007 · Cited by 512
Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 453
Self-citationPersonalized medicine in psychiatry: problems and promises
Ozomaro, U., Wahlestedt, C., & Nemeroff, C. B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-132 · Cited by 270
Milosavljevic, F., Bukvic, N., Pavlovic, Z., Miljevic, C., Pešic, V., Molden, E., Ingelman-Sundberg, M., Leucht, S., & Jukic, M. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3643 · Cited by 218
Zobdeh, F., Eremenko, I. I., Akan, M. A., Tarasov, V. V., Chubarev, V. N., Schiöth, H. B., & Mwinyi, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061190 · Cited by 45
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45
Claudio‐Campos, K., Padrón, A., Jerkins, G., Nainaparampil, J., Nelson, R., Martin, A., Wiisanen, K., Smith, D. M., Strekalova, Y., Marsiske, M., et al. (2021) · Clinical and Translational Science · doi:10.1111/cts.12914 · Cited by 24
Metadata
- Authors
- Stingl, J. C., Brockmöller, J., & Viviani, R.
- Venue
- Molecular Psychiatry
- Published
- 2012-05-08
- Volume
- 18
- Issue
- 3
- Pages
- 273-287
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W1979566817
- Cited by
- 198
- References
- 8
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.